600594 益佰制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.359-14.091-11.8053.599-14.140
总资产报酬率 ROA (%)-0.863-8.740-7.2952.227-9.137
投入资产回报率 ROIC (%)-0.991-10.031-8.3382.563-10.474

边际利润分析
销售毛利率 (%)57.92459.66261.84869.47170.963
营业利润率 (%)-6.104-16.318-14.3634.870-13.745
息税前利润/营业总收入 (%)-4.303-15.622-14.3865.245-13.116
净利润/营业总收入 (%)-8.071-18.001-15.3943.239-16.442

收益指标分析
经营活动净收益/利润总额(%)75.76244.41078.423150.494-53.505
价值变动净收益/利润总额(%)0.0250.069-0.1020.0220.042
营业外收支净额/利润总额(%)-4.9292.4916.095-3.8074.107

偿债能力分析
流动比率 (X)1.7021.5931.8442.2261.740
速动比率 (X)1.0650.9911.2041.5951.207
资产负债率 (%)34.03534.02936.43234.34735.839
带息债务/全部投入资本 (%)21.98521.36123.89221.84125.137
股东权益/带息债务 (%)330.593342.726290.853328.028281.679
股东权益/负债合计 (%)186.606186.794166.696182.676170.342
利息保障倍数 (X)-2.841-14.049-15.8319.479-10.769

营运能力分析
应收账款周转天数 (天)37.28934.65834.64333.28641.814
存货周转天数 (天)324.014276.584259.207253.296267.364